244 reports of this reaction
1.3% of all BETAMETHASONE VALERATE reports
#17 most reported adverse reaction
DYSPEPSIA is the #17 most commonly reported adverse reaction for BETAMETHASONE VALERATE, manufactured by Alembic Pharmaceuticals Inc.. There are 244 FDA adverse event reports linking BETAMETHASONE VALERATE to DYSPEPSIA. This represents approximately 1.3% of all 18,273 adverse event reports for this drug.
Patients taking BETAMETHASONE VALERATE who experience dyspepsia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPEPSIA is a less commonly reported adverse event for BETAMETHASONE VALERATE, but still significant enough to appear in the safety profile.
In addition to dyspepsia, the following adverse reactions have been reported for BETAMETHASONE VALERATE:
The following drugs have also been linked to dyspepsia in FDA adverse event reports:
DYSPEPSIA has been reported as an adverse event in 244 FDA reports for BETAMETHASONE VALERATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPEPSIA accounts for approximately 1.3% of all adverse event reports for BETAMETHASONE VALERATE, making it a notable side effect.
If you experience dyspepsia while taking BETAMETHASONE VALERATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.